Mitsubishi Chemical cuts full-year earnings forecast on market woes, restructuring costs

Mitsubishi Chemical Group has revised its full-year consolidated earnings forecast for the fiscal year ending March 2026, lowering expected core operating profit by 5.7% to JPY 250 bn. This adjustment is primarily due to a decline in market conditions affecting the MMA & Derivatives and Basic Materials & Polymers segments, leading to reduced sales and profit margins. Consolidated revenue is now projected at JPY 3,672,000 million, a 1.8% decrease from the previous forecast, with basic earnings per share expected to be JPY 91.21.

The revised forecast also incorporates an anticipated extraordinary loss in the second half related to structural reform initiatives, further impacting operating profit, profit for the period, and profit attributable to owners of the parent. Despite robust demand in the Specialty Materials segment, overall profit is expected to be lower than initially projected. The company also announced the completion of the absorption-type split agreement for Mitsubishi Tanabe Pharma Corporation and its subsidiaries, which transferred their businesses as of July 1, 2025.

In other news, Mitsubishi Chemical Group completed the acquisition of Coregas Pty Ltd and other entities operating industrial gas businesses in Australia and New Zealand as of July 1, 2025. Additionally, the company's board resolved to cancel 64,820,900 shares of its common stock, representing 4.3% of the outstanding shares before the cancellation, effective October 28, 2025, reducing the total outstanding shares to 1,441,467,207.